Cosmo Pharmaceuticals N.V.

SWX:COPN Stock Report

Market Cap: CHF 982.0m

Cosmo Pharmaceuticals Valuation

Is COPN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COPN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COPN (CHF61.2) is trading below our estimate of fair value (CHF789.79)

Significantly Below Fair Value: COPN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COPN?

Key metric: As COPN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COPN. This is calculated by dividing COPN's market cap by their current earnings.
What is COPN's PE Ratio?
PE Ratio15.1x
Earnings€69.57m
Market Cap€1.05b

Price to Earnings Ratio vs Peers

How does COPN's PE Ratio compare to its peers?

The above table shows the PE ratio for COPN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.8x
DESN Dottikon ES Holding
39.6xn/aCHF 3.0b
SKAN SKAN Group
53.3x18.7%CHF 1.7b
NOVN Novartis
16.6x7.0%CHF 175.3b
TECN Tecan Group
25.7x14.8%CHF 2.6b
COPN Cosmo Pharmaceuticals
15.1x17.2%CHF 982.0m

Price-To-Earnings vs Peers: COPN is good value based on its Price-To-Earnings Ratio (15.1x) compared to the peer average (33.8x).

Price to Earnings Ratio vs Industry

How does COPN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
COPN 15.1xIndustry Avg. 19.3xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COPN is good value based on its Price-To-Earnings Ratio (15.1x) compared to the European Pharmaceuticals industry average (19.3x).

Price to Earnings Ratio vs Fair Ratio

What is COPN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COPN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.1x
Fair PE Ratio18.2x

Price-To-Earnings vs Fair Ratio: COPN is good value based on its Price-To-Earnings Ratio (15.1x) compared to the estimated Fair Price-To-Earnings Ratio (18.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COPN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 61.20
CHF 97.30
+59.0%
22.2%CHF 132.49CHF 78.92n/a4
Dec ’25CHF 63.20
CHF 97.30
+54.0%
22.2%CHF 132.49CHF 78.92n/a4
Nov ’25CHF 68.10
CHF 97.19
+42.7%
23.0%CHF 133.30CHF 76.59n/a4
Oct ’25CHF 74.90
CHF 96.89
+29.4%
23.1%CHF 132.99CHF 76.32n/a4
Sep ’25CHF 79.90
CHF 97.14
+21.6%
22.9%CHF 132.96CHF 76.63n/a4
Aug ’25CHF 74.60
CHF 97.14
+30.2%
22.9%CHF 132.96CHF 76.63n/a4
Jul ’25CHF 70.80
CHF 93.19
+31.6%
15.2%CHF 112.82CHF 78.44n/a4
Jun ’25CHF 70.80
CHF 93.09
+31.5%
13.5%CHF 109.09CHF 79.54n/a4
May ’25CHF 72.30
CHF 93.09
+28.8%
13.5%CHF 109.09CHF 79.54n/a4
Apr ’25CHF 71.30
CHF 93.00
+30.4%
13.7%CHF 109.38CHF 79.27n/a4
Mar ’25CHF 67.10
CHF 75.96
+13.2%
10.0%CHF 83.49CHF 65.58n/a3
Feb ’25CHF 62.20
CHF 75.96
+22.1%
10.0%CHF 83.49CHF 65.58n/a3
Jan ’25CHF 50.90
CHF 73.12
+43.7%
11.3%CHF 84.75CHF 66.58n/a3
Dec ’24CHF 42.75
CHF 73.36
+71.6%
10.7%CHF 84.41CHF 67.77CHF 63.203
Nov ’24CHF 35.20
CHF 73.97
+110.1%
10.6%CHF 85.09CHF 68.37CHF 68.103
Oct ’24CHF 39.90
CHF 73.97
+85.4%
10.6%CHF 85.09CHF 68.37CHF 74.903
Sep ’24CHF 44.55
CHF 68.10
+52.9%
17.2%CHF 85.12CHF 52.03CHF 79.904
Aug ’24CHF 44.80
CHF 74.16
+65.5%
10.1%CHF 85.55CHF 66.89CHF 74.604
Jul ’24CHF 45.25
CHF 77.41
+71.1%
7.9%CHF 85.09CHF 67.97CHF 70.804
Jun ’24CHF 47.00
CHF 80.45
+71.2%
12.9%CHF 96.55CHF 67.59CHF 70.804
May ’24CHF 53.90
CHF 80.45
+49.3%
12.9%CHF 96.55CHF 67.59CHF 72.304
Apr ’24CHF 56.80
CHF 81.83
+44.1%
12.6%CHF 97.03CHF 67.93CHF 71.304
Mar ’24CHF 60.30
CHF 81.70
+35.5%
12.8%CHF 97.22CHF 67.99CHF 67.104
Feb ’24CHF 67.40
CHF 83.59
+24.0%
12.3%CHF 99.80CHF 71.50CHF 62.204
Jan ’24CHF 61.20
CHF 83.61
+36.6%
13.7%CHF 98.40CHF 70.50CHF 50.903
Dec ’23CHF 62.80
CHF 84.07
+33.9%
16.5%CHF 97.95CHF 70.18CHF 42.752

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 01:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cosmo Pharmaceuticals N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Pfeifer-RossiBank am Bellevue
Silvia SchanzBank Vontobel AG
Laura HindleyBerenberg